Patrick R. Conlon

976 total citations
30 papers, 668 citations indexed

About

Patrick R. Conlon is a scholar working on Radiology, Nuclear Medicine and Imaging, Molecular Biology and Oncology. According to data from OpenAlex, Patrick R. Conlon has authored 30 papers receiving a total of 668 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Radiology, Nuclear Medicine and Imaging, 11 papers in Molecular Biology and 10 papers in Oncology. Recurrent topics in Patrick R. Conlon's work include HER2/EGFR in Cancer Research (8 papers), Monoclonal and Polyclonal Antibodies Research (8 papers) and Glioma Diagnosis and Treatment (7 papers). Patrick R. Conlon is often cited by papers focused on HER2/EGFR in Cancer Research (8 papers), Monoclonal and Polyclonal Antibodies Research (8 papers) and Glioma Diagnosis and Treatment (7 papers). Patrick R. Conlon collaborates with scholars based in United States, Czechia and Switzerland. Patrick R. Conlon's co-authors include Jane M. Sayer, Yanrong Wu, Weihong Tan, Chaoyong Yang, Yan Chen, Youngmi Kim, Ángel A. Martí, Nathan Stevens, Steffen Jockusch and Nicholas J. Turro and has published in prestigious journals such as Journal of the American Chemical Society, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Patrick R. Conlon

27 papers receiving 656 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Patrick R. Conlon United States 12 317 146 136 88 84 30 668
Nathan A. Sieracki United States 8 471 1.5× 171 1.2× 169 1.2× 54 0.6× 67 0.8× 9 900
Joshua J. Woods United States 16 295 0.9× 142 1.0× 202 1.5× 74 0.8× 83 1.0× 38 878
Marina A. Orlova Russia 11 126 0.4× 84 0.6× 93 0.7× 39 0.4× 39 0.5× 27 420
Travis R. Besanger Canada 14 286 0.9× 93 0.6× 118 0.9× 98 1.1× 112 1.3× 15 631
Georgiana Surpateanu France 14 151 0.5× 290 2.0× 57 0.4× 27 0.3× 55 0.7× 54 635
Aruna Wijeratne United States 15 190 0.6× 67 0.5× 48 0.4× 91 1.0× 142 1.7× 29 544
Fangfang Meng China 15 311 1.0× 58 0.4× 290 2.1× 117 1.3× 361 4.3× 41 788
Xia Wu China 13 147 0.5× 69 0.5× 246 1.8× 109 1.2× 152 1.8× 50 610
Wenting Yin China 12 188 0.6× 79 0.5× 348 2.6× 101 1.1× 366 4.4× 23 655
Jan Lj. Miljković Germany 13 365 1.2× 79 0.5× 47 0.3× 44 0.5× 104 1.2× 20 1.1k

Countries citing papers authored by Patrick R. Conlon

Since Specialization
Citations

This map shows the geographic impact of Patrick R. Conlon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patrick R. Conlon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patrick R. Conlon more than expected).

Fields of papers citing papers by Patrick R. Conlon

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Patrick R. Conlon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patrick R. Conlon. The network helps show where Patrick R. Conlon may publish in the future.

Co-authorship network of co-authors of Patrick R. Conlon

This figure shows the co-authorship network connecting the top 25 collaborators of Patrick R. Conlon. A scholar is included among the top collaborators of Patrick R. Conlon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Patrick R. Conlon. Patrick R. Conlon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Price, Mackenzie, Justin Low, Patrick R. Conlon, et al.. (2025). Improvements in survival for glioblastoma in the post-Stupp protocol era. Neuro-Oncology. 27(9). 2484–2486.
2.
3.
4.
Ballo, Matthew T., Patrick R. Conlon, Gitit Lavy-Shahaf, et al.. (2023). Tumor Treating Fields (TTFields) for Newly Diagnosed Glioblastoma in the Real World: A Systematic Review and Survival Meta-Analysis. International Journal of Radiation Oncology*Biology*Physics. 117(2). e85–e85. 2 indexed citations
5.
Ballo, Matthew T., Patrick R. Conlon, Gitit Lavy-Shahaf, et al.. (2023). TUMOUR TREATING FIELDS (TTFIELDS) THERAPY IN NEWLY DIAGNOSED GLIOBLASTOMA: A META-ANALYSIS AND SYSTEMATIC REVIEW OF REAL-WORLD SURVIVAL DATA. Neuro-Oncology. 25(Supplement_3). iii16–iii16.
6.
Ballo, Matthew T., Patrick R. Conlon, Gitit Lavy-Shahaf, et al.. (2023). Association of Tumor Treating Fields (TTFields) therapy with survival in newly diagnosed glioblastoma: a systematic review and meta-analysis. Journal of Neuro-Oncology. 164(1). 1–9. 40 indexed citations
7.
Ballo, Matthew T., Patrick R. Conlon, Gitit Lavy-Shahaf, et al.. (2023). Real-world experience with tumor treating fields (TTFields) in newly diagnosed glioblastoma: A survival meta-analysis with systematic review.. Journal of Clinical Oncology. 41(16_suppl). 2059–2059. 1 indexed citations
8.
Conlon, Patrick R., Michael D. Kaufman, Yuanyuan Li, et al.. (2022). Process Development and GMP Production of a Conjugate Warhead: Auristatin F-HPA-Ala/TFA (XMT-1864/TFA). Organic Process Research & Development. 26(8). 2124–2137. 1 indexed citations
9.
Conlon, Patrick R., et al.. (2022). The Effect of Discharge Frequency of a Gas–Liquid Plasma Reactor on Bulk Liquid Transport and Removal of Organic Contaminants. Plasma Chemistry and Plasma Processing. 42(4). 759–783. 18 indexed citations
10.
Duvall, Jeremy R., Marc Damelin, Barrett J. Nehilla, et al.. (2019). Abstract 232: An antibody-drug conjugate carrying a microtubule inhibitor and a DNA alkylator exerts both mechanisms of action on tumor cells. Cancer Research. 79(13_Supplement). 232–232. 4 indexed citations
11.
Toader, Dorin, Marc Damelin, Anouk Dirksen, et al.. (2019). Abstract 2687: Dolasynthen–a novel, homogeneous Auristatin F hydroxypropyl amide antibody-drug conjugate platform. Cancer Research. 79(13_Supplement). 2687–2687. 1 indexed citations
12.
Gumerov, Dmitry R., Elena Ter‐Ovanesyan, Patrick R. Conlon, et al.. (2017). Abstract 48: Non-clinical pharmacokinetics of XMT-1522, a HER2 targeting auristatin-based antibody drug conjugate. Cancer Research. 77(13_Supplement). 48–48. 11 indexed citations
13.
14.
Chen, Yan, Chaoyong Yang, Yanrong Wu, et al.. (2008). Light‐Switching Excimer Beacon Assays For Ribonuclease H Kinetic Study. ChemBioChem. 9(3). 355–359. 47 indexed citations
15.
Kiesman, William F., Jin Zhao, Patrick R. Conlon, et al.. (2006). Norbornyllactone-substituted xanthines as adenosine A1 receptor antagonists. Bioorganic & Medicinal Chemistry. 14(11). 3654–3661. 16 indexed citations
16.
Vu, Chi B., William F. Kiesman, Patrick R. Conlon, et al.. (2006). Tricyclic Imidazoline Derivatives as Potent and Selective Adenosine A1Receptor Antagonists. Journal of Medicinal Chemistry. 49(24). 7132–7139. 13 indexed citations
17.
Peng, Hairuo, Sha Li, Patrick R. Conlon, et al.. (2005). First Synthesis of Piperazine-derived [1,2,4]Triazolo[1,5-a]pyrazine as an Adenosine A2A Receptor Antagonist. Heterocycles. 65(10). 2321–2321. 3 indexed citations
18.
Yao, Gang, Sha Li, G. Kumaravel, et al.. (2004). Synthesis of alkyne derivatives of a novel triazolopyrazine as A2A adenosine receptor antagonists. Bioorganic & Medicinal Chemistry Letters. 15(3). 511–515. 47 indexed citations
19.
Conlon, Patrick R. & Jane M. Sayer. (1979). Thiol catalysis of geometric isomerization of benzaldehyde semicarbazone by nucleophilic addition. The Journal of Organic Chemistry. 44(2). 262–267. 7 indexed citations
20.
Sayer, Jane M., et al.. (1979). Reduction of 1,3-dimethyl-5-(p-nitrophenylimino)barbituric acid by thiols. A high-velocity flavin model reaction with an isolable intermediate. Journal of the American Chemical Society. 101(7). 1890–1893. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nathan A. Sieracki Breakdown of academic impact, for papers by Joshua J. Woods Breakdown of academic impact, for papers by Marina A. Orlova Breakdown of academic impact, for papers by Travis R. Besanger Breakdown of academic impact, for papers by Georgiana Surpateanu Breakdown of academic impact, for papers by Aruna Wijeratne Breakdown of academic impact, for papers by Fangfang Meng Breakdown of academic impact, for papers by Xia Wu Breakdown of academic impact, for papers by Wenting Yin Breakdown of academic impact, for papers by Jan Lj. Miljković
Rankless by CCL
2026